Prot #CX-839-012: A Phase 1b/2, Open label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination with the CDK4/6 Inhibitor Palbociclib in Patients with Advanced or Metastatic Solid Tumors

Project: Research project

Project Details

StatusFinished
Effective start/end date7/21/20 → 7/21/23

Funding

  • Calithera Biosciences, Inc. (Prot #CX-839-012)